BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL-A Pilot Study.

Stoffel, Tanja; Bacher, Ulrike; Banz, Yara; Daskalakis, Michael; Novak, Urban; Pabst, Thomas (2022). BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL-A Pilot Study. Journal of clinical medicine, 11(13) MDPI 10.3390/jcm11133748

[img]
Preview
Text
jcm-11-03748.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (272kB) | Preview

(1) Introduction: BEAM is a high-dose chemotherapy (HDCT) frequently administered before autologous stem cell transplantation (ASCT) in diffuse large B-cell lymphoma (DLBCL). Bendamustine replacing BCNU (BeEAM) is similarly effective at lower toxicities. However, relapse remains the major cause of death in DLBCL. (2) Methods: This is a 12-patient pilot study of the BeEAM preparative regimen with additional polatuzumab vedotin (PV, targeting CD79b) aiming to establish feasibility and to reduce toxicity without increasing the early progression rate. PV was given once at the standard dose of 1.8 mg/kg at day -6 together with BeEAM-HDCT (days -7 to -1) before ASCT. (3) Results: 8/12 patients (67%) received PV with BeEAM as a consolidation of first-line treatment, and 4/12 patients (33%) received PV with BeEAM after relapse treatment. All patients experienced complete engraftment (neutrophils: median 11 days; platelets: 13 days). Gastrointestinal toxicities occurred in 7/12 patients (58%, grade 3). All patients developed neutropenic infections with at least one identified pathogen (bacterial: 10/12 patients; viral: 2/12; and fungal: 1/12). The complete remission rate by PET-CT 100 days post-ASCT was 92%, with one mortality due to early progression. Eleven out of twelve patients (92%) were alive without progression after a median follow-up of 15 months. (4) Conclusions: Our study with 12 patients suggests that combining PV with BeEAM HDCT is feasible and safe, but the limited cohort prevents definite conclusions regarding efficacy. Larger cohorts must be evaluated.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Bacher, Vera Ulrike; Banz Wälti, Yara Sarah; Daskalakis, Michael; Novak, Urban and Pabst, Thomas Niklaus

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

2077-0383

Publisher:

MDPI

Language:

English

Submitter:

Pubmed Import

Date Deposited:

11 Jul 2022 15:20

Last Modified:

11 Jul 2022 15:30

Publisher DOI:

10.3390/jcm11133748

PubMed ID:

35807041

Uncontrolled Keywords:

DLBCL Pola-BeEAM autologous stem cell transplantation bendamustine conditioning regimen high-dose chemotherapy polatuzumab vedotin

BORIS DOI:

10.48350/171212

URI:

https://boris.unibe.ch/id/eprint/171212

Actions (login required)

Edit item Edit item
Provide Feedback